Skip to main content
Clinical Trials/JPRN-UMIN000045409
JPRN-UMIN000045409
Recruiting
未知

A study on the prevention of exacerbation of oral mucositis by early initiation of Episil oral liquid in hematopoietic stem cell transplant recipients and head and neck cancer patients - A study on prevention of oral mucositis exacerbation by early initiation of Episil oral liquid

Fujita Health University0 sites90 target enrollmentSeptember 7, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
Head and neck cancer, Hematological malignancy
Sponsor
Fujita Health University
Enrollment
90
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 7, 2021
End Date
March 31, 2024
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Patients who need assistance in using Episil. 2\) Patients with lesions including the central nervous system (CNS), or having confirmed/suspected of metastasis/invasion in the CNS 3\) Patients using opioids for pain management prior to the start of Episil administration. 4\) Patients with serious infections or complication. 5\) Patients with known allergy to any of the ingredients in Episil. 6\) Patients judged to be inappropriate by the investigator.

Outcomes

Primary Outcomes

Not specified

Similar Trials